TY - JOUR
T1 - Effect of Endovascular Thrombectomy for Acute Ischemic Stroke on Cognitive Outcomes A Secondary Analysis of the ESCAPE Trial
AU - for the ESCAPE Trial Investigators
AU - Joundi, Raed A.
AU - Smith, Eric E.
AU - Mandzia, Jennifer
AU - Ganesh, Aravind
AU - Menon, Bijoy K.
AU - Rempel, Jeremy L.
AU - Thornton, John
AU - Roy, Daniel
AU - Jovin, Tudor G.
AU - Dowlatshahi, Dar
AU - Frei, Donald F.
AU - Bharatha, Aditya
AU - Poppe, Alexandre
AU - Silver, Frank L.
AU - Shuaib, Ashfaq
AU - Teitelbaum, Jeanne S.
AU - Williams, David
AU - Bang, Oh Young
AU - Sapkota, Biggya L.
AU - Burns, Paul
AU - Choe, Hana
AU - Heo, Jie Hoe
AU - Kelly, Michael E.
AU - Linares, Guillermo
AU - Shankar, Jai J.
AU - Sohn, Sung Il
AU - Swartz, Richard H.
AU - Barber, Philip
AU - Coutts, Shelagh B.
AU - Demchuk, Andrew
AU - Goyal, Mayank
AU - Hill, Michael D.
N1 - Publisher Copyright:
Copyright © 2024 American Academy of Neurology.
PY - 2024/5/13
Y1 - 2024/5/13
N2 - Background and Objectives The effect of endovascular therapy (EVT) for large vessel occlusion stroke on cognitive outcomes is not well understood. We evaluated the effect of EVT on cognitive function in the Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE) trial. Methods Patient data from the ESCAPE randomized trial were analyzed. Cognitive assessments completed at 90 days after stroke were the Montreal Cognitive Assessment (MoCA), the Sunnybrook Neglect Assessment Procedure (SNAP), the Boston Naming Test (BNT), Trail-making test A (Trails A), and Trail-making test B (Trails B). We used logistic regression to evaluate the association between EVT and favorable cognitive outcome on the 5 separate tests, adjusting for demographic and clinical factors. We used generalized estimating equations and ordinal regression to determine the odds of favorable outcome with EVT on global cognition incorporating the 5 tests. We added final infarct volume (FIV) to the models to assess the relationship of FIV with cognitive outcome. Results The ESCAPE trial included 315 patients, 165 randomized to EVT and 150 randomized to control. There was higher odds of favorable outcome with EVT for MoCA (adjusted odds ratio [aOR] 2.32, 95% CI 1.30–4.16), SNAP (aOR 3.85, 95% CI 2.00–7.45), BNT (aOR 2.33, 95% CI 1.30–4.17), trails A (aOR 3.50, 95% CI 1.93–6.36), and trails B (aOR 2.56, 95% CI 1.46–4.48). There was higher odds of favorable outcome with EVT on global binary (aOR 2.57, 95% CI 1.67–3.94) and ordinal analyses (aOR 2.83, 95% CI 1.68–4.76) of cognitive function. After adding FIV to the models, both FIV and EVT were significantly associated with cognitive outcome. There was a significant correlation between global cognitive performance and mRS at day 90 (r = −0.78, p < 0.001), with the largest reductions in favorable cognitive outcome from mRS score 4 to 5 and from mRS 2 to 3. Discussion In this secondary analysis of the ESCAPE trial, EVT was associated with favorable outcome on 5 separate cognitive tests and in global analyses of cognitive benefit. These results provide novel evidence for the effect of EVT on cognition and support the global benefit of treatment with EVT. Classification of Evidence This study provides Class II evidence that in patients with acute ischemic stroke due to intracranial internal carotid artery (ICA) or M1 segment MCA occlusion, including tandem extracranial ICA occlusions, EVT compared with best medical therapy increased odds of favorable cognitive outcome.
AB - Background and Objectives The effect of endovascular therapy (EVT) for large vessel occlusion stroke on cognitive outcomes is not well understood. We evaluated the effect of EVT on cognitive function in the Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE) trial. Methods Patient data from the ESCAPE randomized trial were analyzed. Cognitive assessments completed at 90 days after stroke were the Montreal Cognitive Assessment (MoCA), the Sunnybrook Neglect Assessment Procedure (SNAP), the Boston Naming Test (BNT), Trail-making test A (Trails A), and Trail-making test B (Trails B). We used logistic regression to evaluate the association between EVT and favorable cognitive outcome on the 5 separate tests, adjusting for demographic and clinical factors. We used generalized estimating equations and ordinal regression to determine the odds of favorable outcome with EVT on global cognition incorporating the 5 tests. We added final infarct volume (FIV) to the models to assess the relationship of FIV with cognitive outcome. Results The ESCAPE trial included 315 patients, 165 randomized to EVT and 150 randomized to control. There was higher odds of favorable outcome with EVT for MoCA (adjusted odds ratio [aOR] 2.32, 95% CI 1.30–4.16), SNAP (aOR 3.85, 95% CI 2.00–7.45), BNT (aOR 2.33, 95% CI 1.30–4.17), trails A (aOR 3.50, 95% CI 1.93–6.36), and trails B (aOR 2.56, 95% CI 1.46–4.48). There was higher odds of favorable outcome with EVT on global binary (aOR 2.57, 95% CI 1.67–3.94) and ordinal analyses (aOR 2.83, 95% CI 1.68–4.76) of cognitive function. After adding FIV to the models, both FIV and EVT were significantly associated with cognitive outcome. There was a significant correlation between global cognitive performance and mRS at day 90 (r = −0.78, p < 0.001), with the largest reductions in favorable cognitive outcome from mRS score 4 to 5 and from mRS 2 to 3. Discussion In this secondary analysis of the ESCAPE trial, EVT was associated with favorable outcome on 5 separate cognitive tests and in global analyses of cognitive benefit. These results provide novel evidence for the effect of EVT on cognition and support the global benefit of treatment with EVT. Classification of Evidence This study provides Class II evidence that in patients with acute ischemic stroke due to intracranial internal carotid artery (ICA) or M1 segment MCA occlusion, including tandem extracranial ICA occlusions, EVT compared with best medical therapy increased odds of favorable cognitive outcome.
UR - https://www.scopus.com/pages/publications/85192949933
U2 - 10.1212/WNL.0000000000209270
DO - 10.1212/WNL.0000000000209270
M3 - Article
C2 - 38739880
AN - SCOPUS:85192949933
SN - 0028-3878
VL - 102
JO - Neurology
JF - Neurology
IS - 10
M1 - e209270
ER -